Compare Novo Nordisk A/S (NVO) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Schlumberger NV — how do they compare? Novo Nordisk A/S trades at $46.02 (market cap $207.85B), while Schlumberger NV trades at $53.7 (market cap $79.67B). The key difference: Novo Nordisk A/S is far larger — about 2.6× Schlumberger NV's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | SLB | |
|---|---|---|
Market Cap | $207.85B | $79.67B |
Sector | Health | Energy |
52-Week High | $63.98 | $58.01 |
52-Week Low | $35.29 | $31.72 |
Enterprise Value | $222.55B | $88.40B |
Dividend Yield | 3.81% | 2.2% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
